Cancer News

Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee (07/17/2019)

(July 8, 2019, Bethesda, MD) Today, the Bladder Cancer Advocacy Network (BCAN) announced the recipient of its prestigious Bladder Cancer Research Innovation Award. This year’s awardee is Philip Beachy, Ph.D., Professor of Urology and of Developmental Biology at the Stanford University School of Medicine. His research project will address the need for better treatments for... Continue Reading

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma (04/16/2019)

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today,... Continue Reading

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (06/06/2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium™ for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall 43% of patients achieved a complete response and Vicinium appears to represent an emerging treatment option. About Vicinium™ Vicinium™, …

Continue reading "Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer"

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (05/04/2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS™ (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative intent therapy. About Muscle Invasive Bladder Cancer Bladder cancer is the fifth most common neoplasm in industrialized countries, affecting …

Continue reading "U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer"

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (04/03/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a …

Continue reading "Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer"

Keytruda Improves Survival of Advanced Bladder Cancer (02/26/2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary Cancer Symposium.1 About Bladder Cancer Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average …

Continue reading "Keytruda Improves Survival of Advanced Bladder Cancer"

Avelumab Immunotherapy Approved for Bladder Cancer (05/15/2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- CancerConnect. About Urothelial Cancer Bladder …

Continue reading "Avelumab Immunotherapy Approved for Bladder Cancer"

FDA Approves Imfinzi for Treatment of Urothelial Cancer (05/11/2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of treatment with that chemotherapy. Bladder cancer is the most common type …

Continue reading "FDA Approves Imfinzi for Treatment of Urothelial Cancer"

FDA Approves Opdivo for Treatment of Bladder Cancer (02/16/2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing chemotherapy. Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. …

Continue reading "FDA Approves Opdivo for Treatment of Bladder Cancer"

Tecentriq® Approved for Bladder Cancer (06/08/2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is … Continue reading "Tecentriq® Approved for Bladder Cancer"